01.12.2015 | Research article | Ausgabe 1/2015 Open Access

Diagnostic accuracy of nasal nitric oxide for establishing diagnosis of primary ciliary dyskinesia: a meta-analysis
- Zeitschrift:
- BMC Pulmonary Medicine > Ausgabe 1/2015
Competing interests
Authors’ contributions
Authors’ information
Background
Methods
Search strategy and selection criteria
Data extraction
Analysis
Results
Eligible studies
Study characteristics
#
|
Author/Study
|
Country
|
Study Design
|
Study Population
a
|
Age range (yrs)
(Mean, range/SD)
|
Analyzer
|
Flow rate (L/min)
|
Measurement Method
b
|
Cut – off (nL/min)
|
Inclusion criteria/ Diagnosis
|
---|---|---|---|---|---|---|---|---|---|---|
1
|
Narang I (2002) [
26]
|
United Kingdom
|
Case - Control
|
31 PCD
53 HC
|
PCD: 11.0 (5.5–17.3)
HC: 10.7 (5.5–19.0)
|
LR 2000
|
0.25
|
BH
|
62.5
|
HSVM and TEM
|
2
|
Corbelli R (2004) [
23]
|
Switzerland
|
Prospective Cohort
|
17 PCD
17 non PCD (BE,B)
|
All: 11.4 (1.2)
|
CLD88sp
|
1.20
|
BH
|
126
|
TEM
|
3
|
Piacentini G (2008) [
25]
|
Italy
|
Case - Control
|
10 PCD
27 HC
|
PCD: 17 (−)
HC: 7 (−)
|
NIOX Flex
|
0.30
|
BH
|
21.3
|
TEM
|
4
|
Mateos Coral D (2011) [
31]
|
Canada
|
Case – Control (with longitudinal follow-up in a subsample)
|
20 PCD
65 non PCD (CF,BE,HC)
|
PCD: 11.4 (3.5)
HC: 11.0 (3.7)
CF: 11.0 (3.4)
BE: 10.9(3.3)
|
CLD88sp
|
0.33
|
ER & TB
|
ER: 58.5
TB: 37.1
|
TEM
|
5
|
Marthin JK (2011) [
22]
Substudy 3
|
Denmark
|
Prospective Cohort
|
20 PCD
97 non PCD
|
All: 6.9 (0.0–62.4)
c
|
NIOX Flex
|
0.30
|
BH & TB
|
BH: 52.5
TB: 47.4
|
HSVM and TEM
|
6
|
Marthin JK (2011) [
22]
Substudy 2
|
Denmark
|
Case - Control
|
59 PCD
57 HC
|
PCD: 17.4 (3.6–65.8)
c
Non PCD:29.5 (3.1–63.6)
c
|
NIOX Flex
|
0.30
|
BH & TB
|
BH: 52.5
TB: 47.4
|
HSVM and/or TEM
|
7
|
Leigh M (2013) [
7]
|
United States
|
Prospective Cohort
|
71 PCD
84 non-PCD
|
PCD: 23.3(18)
Non PCD: 31.8 (22.3)
|
Sievers 280i
CLD88sp
NIOX Flex
|
0.50
0.33
0.30
|
ER
|
76.9
|
TEM and DNA
|
8
|
Boon M (2014) [
30]
|
Belgium
|
Case - Control
|
38 PCD
188 non PCD
(HC, CF, Asthma, HID)
|
PCD: 14.3 (8.8–18.1)
c
HC: 14.9 (10.8–20.4)
c
CF: 14.0 (9.2–17.9)
c
Asthma: 12.1 (9.8–16.5)
c
HID: 10.7 (8.2–15.6)
c
|
CLD88sp
|
0.30
|
ER & TB
|
ER: 90
TB: 60
|
HSVM and TEM
(and culture)
|
9
|
Harris A (2014) [
14]
|
United Kingdom
|
Case - Control
|
13 PCD
37 non PCD
(HC,CF, CSLD)
|
PCD: 23 (5–71)
HC: 31 (8–65)
CF: 15(6–29)
CSLD: 36 (8–79)
|
NIOX Flex
NIOX MINO
|
0.30
|
BH & TB
|
BH: 38
TB: 30
|
HSVM and TEM
(and culture for some)
|
10
|
Montella S (2012) [
27]
|
Italy
|
Case - Control
|
23 PCD
23 HC
|
PCD: 15.8 (4.6–32.8)
c
HC: 15.7 (4.3–32.1)
c
|
NIOX MINO
|
0.30
|
TB
|
17.4
|
HSVM and TEM
|
11
|
Santamaria F (2008) [
28]
|
Italy
|
Case - Control
|
14 PCD
14 HC
|
PCD: 15 (7–27)
HC:16 (7–27)
|
NIOX Flex
|
0.28
|
BH
|
7.2
|
TEM
|
12
|
Moreno Caldo A (2010) [
29]
|
Spain
|
Case Control
|
9 PCD
112 non PCD
(HC, CF, Asthma,BE)
|
PCD: − (7–14)
HC: − (−)
CF: − (6–14)
Asthma: (6–17)
BE: − (6–14)
|
LR2000
|
0.25
|
BH
|
28
|
TEM
|
13
|
Beydon M 2015 [
24]
|
France
|
Prospective Cohort
|
49 PCD
37 non-PCD
|
PCD: 11.4 (7,13.9)
d
Non PCD: 7.9 (4.9,11.6)
d
|
NIOX Flex
Endono 8000
|
0.30
|
BH/ER
TB
|
BH/ER: 82.2
TB: 39.9
|
HSVM, TEM and/or DNA
|
Quality assessment
Study
|
Risk of bias
|
Applicability concerns
|
|||||
---|---|---|---|---|---|---|---|
Patient selection
|
Index test
|
Reference Standard
|
Flow and timing
|
Patient selection
|
Index test
|
Reference standard
|
|
Boon 2014 [
30]
|
L
|
U
|
L
|
L
|
L
|
L
|
L
|
Mateos Coral 2011 [
31]
|
U
|
L
|
L
|
L
|
U
|
L
|
L
|
Piacentini 2008 [
25]
|
U
|
L
|
L
|
L
|
U
|
L
|
L
|
Santamaria 2008 [
28]
|
L
|
U
|
L
|
L
|
L
|
L
|
L
|
Montela 2012 [
27]
|
U
|
L
|
U
|
L
|
L
|
L
|
L
|
Corbelli 2004 [
23]
|
L
|
U
|
L
|
L
|
L
|
L
|
L
|
Narang 2002 [
26]
|
L
|
L
|
L
|
L
|
L
|
L
|
L
|
Harris 2014 [
14]
|
L
|
U
|
L
|
L
|
L
|
L
|
L
|
Leigh 2013 [
7]
|
L
|
L
|
L
|
L
|
L
|
L
|
L
|
Marthin 2011 [
22]
|
L
|
U
|
L
|
L
|
L
|
L
|
L
|
Moreno Galdo 2010 [
29]
|
U
|
U
|
L
|
L
|
U
|
L
|
L
|
Beydon M 2015 [
25]
|
L
|
L
|
L
|
U
|
L
|
L
|
L
|